ProlyteORS, the flagship brand of Cipla Health Limited, welcomes the recent directive from the Food Safety and Standards ...

The company is banking on key new launches, including weight loss drug Semaglutide and biosimilar Abatacept to drive growth ...

The week is dominated by central bank activity, featuring three major interest rate decisions from the US Federal Reserve, ...

Tata Capital, Maruti Suzuki India, Urban Company, NTPC, Bank of Baroda and Cipla are among over 300 companies scheduled to ...

From generics glory to a billion-dollar dream of discovery, how Dr. Anji Reddy’s audacious vision reshaped Indian pharma—and ...

Mumbai, Oct. 24 -- "The introduction of a second brand of Tirzepatide in India through our commercial agreement with Cipla ...

Dr Reddy's Laboratories has received approval to manufacture and market generic semaglutide, a weight loss drug, once Novo Nordisk's patent expires in 2026.

Markets end six-day rally as profit booking and trade policy concerns weigh on investor sentiment, with mixed sector ...

Mid-week on Wednesday, October 29th, attention will turn to public sector behemoths Coal India Ltd and Steel Authority of India Ltd (SAIL).

() -Indian generic drugmaker Dr Reddy's Laboratories reported second-quarter profit below estimates on Friday, hurt by higher costs and stiff competition for the generic version of cancer drug ...

DIIs bought shares worth Rs 12,476 crore and sold shares worth Rs 12,303 crore. In contrast, FIIs purchased shares valued at ...

Britain's Medicines and Healthcare products Regulatory Agency seized a large cache of unlicensed weight-loss drugs, including ...